anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
This study will be an open label, single-dose study to evaluate product design clinical performance of a to-be-marketed drug-device combination product (sc2WearTM Furosemide Combination Product) in up to 70 adult male and female Subjects previously diagnosed with mild to advanced heart failure (NYHA Class II-IV). The study was designed and powered to achieve "95/95" performance testing. Methodology: Each Subject will complete Screening, Treatment, and Follow-Up Phases on an outpatient basis. During the Screening Phase, all Subjects who sign the informed consent form and satisfy the inclusion/exclusion criteria will be enrolled into the trial. Drug administration may start on the day of enrollment or be scheduled within 3 days of completion of Screening assessments. However, if the treatment visit doesn't occur within 3 days of initial screening, subjects may be rescreened and treated within 3 days of rescreening. The Treatment Phase comprises a preprogrammed bi-phasic 5 hour drug administration. Treatment Day observations will commence with pre-placement assessments and continue until after device removal. Device preparation, placement and removal will be performed by study staff in accordance with product instructions of use. Removal will occur within 3 hours of completion of drug delivery (8 hours of start of administration). Subjects will return 5-7 days after the Treatment Day for a post treatment follow-up and photography.

Blood samples will be obtained for the measurement of plasma furosemide levels prior to start of the administration and once during the plateau phase (1-5 hours following activation). After preparation of the skin the device will be placed on the upper abdominal area by clinical study staff. Subjects are advised to avoid strenuous physical activity or activities that could expose the device to moisture such as swimming, bathing or showering. Participants will be informed that marked diuresis may ensue after activation, and that they should avoid travel, operating a vehicle or other situations without immediate access to bathroom facilities. For this study, up to 70 unique reusable components (Activator) will be used. Likewise, up to 70 single-use units (Cartridge) will be used. Following removal from the skin, the assembled device will be inspected and photographed by the site staff. The used device (assembled Cartridge and Activator) will be placed in a sealed container and returned for further inspection and measurement of residual volume in the device reservoir by a qualified laboratory.
BACKGROUND: Colorectal cancer (CRC) is a type of neoplasm, developing in the colon or rectum. The exact etiology of CRC is not well known, but the role of genetic, epigenetic, and environmental factors are established in its pathogenesis. Therefore, the aim of this research was to explore the effects of ANRIL polymorphisms on the CRC and its clinical findings.
METHODS AND RESULTS: The peripheral blood specimens were collected from 142 CRC patients and 225 controls referred to Milad Hospital, Tehran, Iran. PCR- RFLP method was used to analyze ANRIL rs1333040, rs10757274 rs4977574, and rs1333048 polymorphisms. The ANRIL rs1333040 polymorphism was related to a higher risk of CRC in the co-dominant, dominant, and log-additive models. ANRIL rs10757274, rs4977574, and rs1333048 polymorphisms showed no effect on CRC susceptibility. The CGAA and TGGA haplotypes of ANRIL rs1333040/ rs10757274/ rs4977574/rs1333048 polymorphisms were associated with the higher and the lower risk of CRC respectively. The rs1333040 polymorphism was associated with higher TNM stages (III and IV). The frequency of ANRIL rs10757274 polymorphism was lower in CRC patients over 50 years of age only in the dominant model. In addition, the rs10757274 was associated with well differentiation in CRC patients.
CONCLUSION: The ANRIL rs1333040 polymorphism was associated with a higher risk of CRC and higher TNM stages. ANRIL rs10757274 polymorphism was associated with the well-differentiated tumor in CRC.
A water-in-oil emulsion composition which, when used as an emulsion makeup base, can be evenly applied and hence enables cosmetics to be spread well. The emulsion composition has a high internal-aqueous-phase proportion that renders the skin fresh and, despite this, gives a sense of thickness, softness, and a moisturizing effect after application. The emulsion composition further has excellent emulsion stability. The water-in-oil emulsion composition is characterized by comprising the following components (A), (B), and (C) and satisfying the following requirements (1) and (2). Components: (A) glycerol isostearate and/or glycerol oleate (B) an aqueous ingredient (C) an oily ingredient comprising a C20 or lower isoparaffin Requirements: (1) The internal-aqueous-phase proportion obtained by dividing the mass of the aqueous ingredient of component (B) by the total mass of the aqueous ingredient of component (B) and the oily ingredient of component (C) is 68% or higher. (2) The amount of glycerol monoisostearate and/or glycerol monooleate contained in component (A) is 85 mass% or larger with respect to the total amount of (A).
PURPOSE: An oral solid formulation containing choline alfoscerate and a method for manufacturing the same are provided to improve stability to moisture, temperature, and light and to enable long-term storage. CONSTITUTION: A pharmaceutical composition comprises: a drug part containing choline alfoscerate or a pharmaceutically acceptable salt thereof; a coating part which is formed at the outside of the drug part and contains a water soluble polymer; and pharmaceutically acceptable additives. The choline alfoscerate is L-alpha-glyceryl phosphoryl choline. An oral solid formulation contains the pharmaceutical composition. The solid formulation is a tablet, a capsule, granules, or a pellet. A method for preparing the pharmaceutical composition comprises: a step of spraying a coating solution containing the water soluble polymers and preparing a drug particle; and a step of adding and mixing the pharmaceutically acceptable additives to the drug particle.
Devices and methods for treating diseases associated with loss of neuronal function by cell replacement therapy are described. The methods are designed to promote proliferation, differentiation, migration, or integration of exogenous stem cells transplanted into the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region having damaged neuronal tissues, into which region exogenous stem cells are transplanted. A therapy may also be applied to a second region of the CNS to which neurons from the damaged CNS region are expected to project. The exogenous stem cells may be transfected with an electrically responsive genetic construct comprising an electrically responsive promoter and a target gene. Expression of the target gene, which may encode a gene product that promotes proliferation, differentiation, migration, or integration of the exogenous stem cell, may be closely controlled by application of an electrical signal.
A gel preparation containing polystyrene-sulfonate for treating hyperpotassemia, wherein the grain size of the polystyrene-sulfonate is regulated within a range of at least 5 to 100  mu m and the viscosity thereof before gelling is controlled by adding thereto a thickener so that the polystyrene-sulfonate grains are homogeneously dispersed. Preferably, the preparation contains agents substitutable for water and thus the moisture content therein is lowered. Since the gel preparation imparts neither any disagreeable feel nor roughness due to the active ingredients at the administration in the oral cavity, it can be taken without resort to water. Moreover it has a small moisture content, which makes it easy to control water intake even in the case of patients under strict moisture intake regulation such as ones with renal insufficiency. Thus, the quality of lift of the patients can be considerably improved. <IMAGE>
To evaluate six intensively studied patients admitted to medical intensive care with pulmonary blastomycosis requiring mechanical ventilation. Interventionally, all patients will receive continuously infused amphotericin-B (1 mg/kg/d); and then stepped down to oral or i.v. voriconazole once clinically responding. Blood will be sampled for amphotericin-B concentrations for the 3 first days (i.e. one blood sample per day); and when eventually changed over to voriconazole (i.e. generally after a total dose of 1 g has been reached of Amphotericin-B; as per usual practice). Once switched to oral or intravenous voriconazole, at the treating physicians discretion, then blood would once again be sampled for the next 3 days for voriconazole concentrations. MIC's of the infecting blastomyces would also be analyzed. The fungal isolate would be sent off to the Fungus Testing Laboratory at the University of Texas in San Antonio for susceptibility testing.

Clinical response to therapy relative to their initial pharmacokinetic and pharmacodynamic indices for amphotericin-B (i.e. daily free maximal concentration divided by the MIC) would be assessed in these 6 intensively studied patients. Clinical parameters assessed would be 1). time to fever defervescence; 2). time to white cell count resolution, and 3). improvements in respiratory gas exchange (i.e. specifically the rate of rise of the pressure of arterial oxygen (Pa02) divided by the fraction of inspired oxygen (Fi02) delivered through the ventilator (or PF ratio).
Amlodipine besylate/atorvastatin calcium tablets contain atorvastatin and are therefore contraindicated in women who are pregnant or may become pregnant. The atorvastatin component of amlodipine besylate/atorvastatin calcium tablets may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia.

There are no adequate and well-controlled studies of atorvastatin use during pregnancy; however in rare reports congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM TABLETS, WHICH INCLUDE ATORVASTATIN, SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus (see PRECAUTIONS, Pregnancy).

It is not known whether atorvastatin or amlodipine are excreted into human milk; however a small amount of another statin does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women taking amlodipine besylate/atorvastatin calcium tablets should not breastfeed their infants (see PRECAUTIONS, Nursing Mothers).
Efavirenz is an HIV-1 specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI). Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its molecular formula is C14H9ClF3NO2 and its structural formula is:  


Efavirenz USP is a white to off-white crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 microgram/mL).  
  
Efavirenz is available as capsules for oral administration containing either 50 mg, 100 mg, or 200 mg of efavirenz USP and the following inactive ingredients: lactose monohydrate, magnesium stearate, sodium lauryl sulfate and sodium starch glycolate (potato). The capsule shell contains gelatin, silicon dioxide and sodium lauryl sulfate. In addition 50 mg contains titanium dioxide and yellow iron oxide, 100 mg contains titanium dioxide and 200 mg contains yellow iron oxide. The capsules are printed with edible ink containing black iron oxide and shellac.
Trichoderma longibrachiatum is a filamentous fungus used as a biological control agent against different plant diseases. The multifunctional secondary metabolites synthesized by Trichoderma, called peptaibols, have emerged as key elicitors in plant innate immunity. This study obtained a high-quality genome sequence for the T. longibrachiatum strain 40418 and identified two peptaibol biosynthetic gene clusters using knockout techniques. The two gene cluster products were confirmed as trilongin AIV a (11-residue) and trilongin BI (20-residue) using liquid chromatography coupled with tandem mass spectrometry. Further investigations revealed that these peptaibols induce plant resistance to Pseudomonas syringae pv tomato (Pst) DC3000 infection while triggering plant immunity and cell death. Notably, the two peptaibols exhibit synergistic effects in plant-microbe signaling interactions, with trilongin BI having a predominant role. Moreover, the induction of tomato resistance against Meloidogyne incognita showed similarly promising results.
The utility model refers to a biologically active polybacterial product, in the form of oral powder or tablets, applicable as a veterinary immunostimulant in acute chronic infections, which are of particular importance for the health and nutrition of animals. The product according to the present utility model contains a polybacterial complex of a substance of killed bacterial bodies and their lysates of strain Escherichia coli 29 expressing type 1 and P files, Escherichia coli Rc mutant and Staphylococcus aureus with a stabilizer in an amount by weight % respectively: polybacterial substance from 30 to 50, stabilizer from 50 to 70, as well as suitable one or more excipients, where each of the two strains of E. coli of the polybacterial substance is in an amount of from 20 to 45 wt. %, and strain St. aureus is in an amount of 20 to 60 wt. %. The amount of agents involved in the dry powder form is in the following weight %, respectively for: the polybacterial complex from 96.9 to 99.9 and for excipient (s) from 0.1 to 3.1, and for the tablet form respectively for the polybacterial complex 35 to 41, and excipient (s) from 59 to 65. The biologically active polybacterial complex, together with the whole bacterial cells used and their lysate in the product according to the present utility model, provide full stimulation of all defense mechanisms of the organism of mammals and birds. The selected excipients with their quantities ensure the stability of the product and improve its taste and efficiency. It is designed for all age groups of animals, incl. newborns - sucklers and weaned, pregnant, lactating mothers, as well as newly hatched birds and laying birds.
The Tuning in to Kids program as developed by Havighurst and colleagues (2010), is selected as one of the parenting intervention programs in this study. It will be extended to 8-week program that aims at equipping parents with emotion coaching skills.
Apparatus and methods for providing a surgical table base with sufficient stiffness and adjustable support members with force feedback are described herein. In some embodiments, a base for a surgical table includes a base body to which other components of a surgical table can be coupled. A surgical table, and optionally a patient supportable by the surgical table, and any equipment to be carried by the surgical table, collectively representing a table load to be carried by the base body to support the surgical table on a surface. The base further includes a support assembly coupled to the base body to support the base body on the surface. The support assembly includes at least four support members. Each support member has a surface-engaging end and can transmit a portion of a total load represented by the weight of the base and the table load through the surface-engaging end to the surface. The surface-engaging ends of any three of the four support members define a plane. One of the support members is adjustable to move the one support member relative to a plane defined by the three of the other support members and thereby to change the portion of the total load carried by one of the support members. The base further includes a load sensor operably coupled to the support assembly and disposed to detect the portion of the total load carried by one of the support members.
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is a completely extrathoracic device. Subsequently, complications differ between these 2 implantable cardioverter-defibrillators, which might impact patient perceptions of the therapies. This prespecified secondary analysis of the PRAETORIAN trial evaluates differences in quality of life.
METHODS: The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) randomized patients with an implantable cardioverter-defibrillator indication, without the need for pacing to S-ICD or TV-ICD therapy. Two questionnaires were collected at baseline, discharge, 12 months, and 30 months. The Duke Activity Status Index measures cardiac-specific physical functioning, and the 36-Item Short Form Health Survey measures physical and mental well-being, with the subscales bodily pain and mental health being of interest in this analysis. Mann-Whitney U tests were used to compare study arms, and a mixed model was used to describe the questionnaire outcomes over time.
RESULTS: Patients were randomized to S-ICD (n=426) and TV-ICD (n=423). In the S-ICD group, 20% were women versus 19% in the TV-ICD group. The median age was 63 (interquartile range, 54-69) years in the S-ICD group versus 64 (interquartile range, 56-69) years in the TV-ICD group. There were no significant differences in the Duke Activity Status Index and 36-Item Short Form Health Survey subscales for bodily pain and mental health between the groups at any time point. Patients with a shock in the last 90 days had significantly lower scores for social functioning (P=0.008) and role limitations due to emotional problems (P=0.001) than patients without a shock, but this effect did not differ between treatment arms.
CONCLUSIONS: In a large randomized cohort of patients with an S-ICD or TV-ICD, no difference in overall quality of life was observed. However, implantable cardioverter-defibrillator shocks resulted in a reduction in quality of life, regardless of the device type or appropriateness.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01296022.
Provided is a humanised anti-human epidermal growth factor receptor (EGFR) antibody and an application thereof. A strain of EGFR mouse monoclonal antibody LA22 is humanised, so that human origin amino acid sequences within the antibody reach more than 90%, and an anti-human EGFR monoclonal antibody is filtered out. The affinity of the binding between the present antibody and a human EGFR is 2.3 nM, equal to a mouse origin antibody. After binding to an EGFR of a tumour cell surface, the present antibody rapidly induces endocytosis of the EGFR of the tumour cell surface, and becomes an ideal biological targeted therapy antibody. The present invention provides a specific antibody drug for EGFR-targeted prevention and treatment of tumours and other diseases such as inflammatory and autoimmune diseases. The risk of the present antibody drug producing human anti-mouse antibodies (HAMA) in a patient can be significantly reduced, the half-life of the antibody drug is extended, and efficacy is improved.
Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
Monitoring

Monitor serum potassium and adjust dosages accordingly. For treatment of hypokalemia, monitor potassium levels daily or more often depending on the severity of hypokalemia until they return to normal. Monitor potassium levels monthly to biannually for maintenance or prophylaxis.

The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.

Administration

Dilute the potassium chloride solution with at least 4 ounces of cold water [see Warnings and Precautions (5.1)]. Take with meals or immediately after eating. If serum potassium concentration is <2.5 mEq/L, use intravenous potassium instead of oral supplementation.
A nucleic acid aptamer specifically recognizing soluble ST2 protein and its application, belonging to the field of variation or genetic engineering, are described. The technical problem addressed includes how to specifically detect sST2 protein. In order to address this technical problem, nucleic acid aptamers of single-stranded DNA with nucleotide sequences are shown in SEQ ID No. 1-10, respectively. SELEX technology, combined with high-throughput sequencing technology and bioinformatics analysis, reduces the rounds of screening and obtains candidate nucleic acid aptamers, and further analyzes its affinity and specificity to obtain a nucleic acid aptamer that specifically recognizes sST2 protein. The nucleic acid aptamer has the characteristics of high specificity, high stability, convenient synthesis, and easy labeling of functional groups, and the like, and may be used for the detection of sST2 protein and the preparation of biosensors, diagnosis and prognosis of cardiovascular diseases and other products.